ARS Pharmaceuticals
SPRY
165 hedge funds and large institutions have $752M invested in ARS Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 61 increasing their positions, 42 reducing their positions, and 19 closing their positions.
95% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 19
45% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 42
9% more funds holding
Funds holding: 151 → 165 (+14)
7.29% more ownership
Funds ownership: 66.08% → 73.37% (+7.3%)
19% less capital invested
Capital invested by funds: $928M → $752M (-$176M)
26% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $3.65M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$53.3M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$15.8M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$9.81M |
| 5 |
Goldman Sachs
New York
|
+$8.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$12.1M |
| 2 |
DM
Deerfield Management
New York
|
-$7.89M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$7.79M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$7.73M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.2M |
SPRY Hedge Fund Activity: Q4 2024 in Review
165 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2024, worth a combined $752M — down 19% from $928M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new SPRY positions and 19 closed out — a net gain of 18 holders — while 61 added to existing stakes and 42 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $53.3M. The largest seller was Franklin Resources, cutting an estimated $12.1M.
- 165 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2024, up from 151 in Q3 2024.
- Funds reported $752M of ARS Pharmaceuticals stock for Q4 2024, down 19% quarter-over-quarter.
- 37 funds opened new ARS Pharmaceuticals positions in Q4 2024 and 19 closed out, a net change of +18 holders.
- The largest ARS Pharmaceuticals buyer in Q4 2024 was AllianceBernstein, an estimated $53.3M added.
- The largest ARS Pharmaceuticals seller in Q4 2024 was Franklin Resources, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2024.